Subcutaneous sumatriptan for the treatment of migraine: Humanistic, economic, and clinical consequences

Family Medicine

Volumn 28, Issue 3, 1996, Pages 171-177

  Cohen, Jeffrey A ^a   Beall, Donna G ^a   Miller, David W ^b   Beck, Arne ^a   Pait, Gayla ^b   Clements, Bill D ^b  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; HEALTH CARE UTILIZATION; HEALTH MAINTENANCE ORGANIZATION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIGRAINE; PAIN ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SEROTONIN AGONISTS; SUMATRIPTAN;

EID: 0030009441     PISSN: 07423225     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Smith R. Management of chronic headache. Can Fam Physician 1989;35:1835-9.
2. Osterhaus JT, Townsend RJ, Gandek B, Ware JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34:337-43.
3. Clouse JC, Osterhaus JT. Health care resource use and costs associated with migraine in a managed health care setting. Pharmacoeconomics 1994;28:659-64.
4. Dahlof C. Assessment of health-related quality of life in migraine. Cephalalgia 1993;13:233-7.
5. de Lissovoy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994;44(suppl 4):S56-62.
6. Solomon GD. Quality of life assessment in patients with headache. Pharmacoeconomics 1994;6:34-41.
7. Osterhaus JT, Gutterman DL. Plachetka JR. Health care resource and lost labor costs of migraine headache in the US. Pharmacoeconomics 1992;2:67-76.
8. Lipton TB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 1993;43(suppl 3):S6-10.
9. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21.
10. Cady RK, Wendt JK, Kirchner JF, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5.
11. Schoenen J, Bulcke J, Caekebeke J, et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study. Cephalalgia 1994;14:55-63.
12. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. Eur Neurol 1991;31:323-31.
13. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996;42:36-42.
14. Solomon GD, Skobieranda FG, Genzen JR. Quality-of-life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449-54.
15. Solomon GD, Nielsen K, Miller DW. The effects of sumatriptan on migraineurs' health-related quality of life: a review of data from clinical trials. Med Interface 1995;8:134-41.
16. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:1-96.
17. Ware JE. SF-36 health survey: manual and interpretation guide. Boston: New England Medical Center, 1993.
18. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36). Med Care 1992;30:473-83.
19. Miller DW, Kirchdoerfer LJ, Shepherd MD. et al. A disease-specific instrument to measure quality-of-life effects attributable to migraine. Poster presentation at the Health Services Research Association 10th Annual Meeting; June 27-29, 1993; Washington, DC.
20. The Oral Sumatriptan Dose-defining Study Group. Sumatriptan - an oral dose-defining study. Eur Neurol 1991;31:300-5.
21. The Oral Sumatriptan International Multiple-dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306-13.